Login
$SRPT
$15.10 -$0.03 (0.19%) After hours

$SRPT SEC Filings

Filed On Filing
13 Nov 2026 13F-HR
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 8-K: Results of Operations and Financial Condition

Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs

05 Nov 2026 10-Q
23 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the Univ...

08 Sep 2026 Form 4: Wong Ryan Ho-Yan, Chief Financial Officer

Gave up 13,272 shares to cover exercise price or tax ($295K)

08 Sep 2026 Form 4: Estepan Ian Michael, Chief Operating Officer

Gave up 24,799 shares to cover exercise price or tax ($551K)

08 Sep 2026 Form 4: Rothfuss Cristin, EVP, General Counsel

Gave up 22,025 shares to cover exercise price or tax ($489K)

08 Sep 2026 Form 4: Rodino-Klapac Louise, President, R&D and Tech Ops

Gave up 21,423 shares to cover exercise price or tax ($476K)

14 Aug 2026 13F-HR
13 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
05 Aug 2026 8-K: Results of Operations and Financial Condition

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

05 Aug 2026 10-Q
31 Jul 2026 SCHEDULE 13G/A
30 Jul 2026 SCHEDULE 13G/A
29 Jul 2026 Form 4: Severino Michael, Director

Received 756,104 shares as a grant or award · Granted 2,224,342 Stock Options (right to buy)

29 Jul 2026 Form 3: Severino Michael, Director

No securities owned

28 Jul 2026 S-8

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support